Launched in 2019 by Deerfield, the Women in Science Translational Research Symposia were created to clarify the process and route to commercialization for women scientists and in turn, help prepare them to advance their discoveries to market. The program is committed to promoting diversity of perspectives in innovation and changing this paradigm through knowledge and network creation.

In 2022, the Women in Science Translational Research Symposia  formally embedded within Advancium Health Network, an independent non-profit organization launched by Deerfield Management and the Deerfield Foundation and continues to be supported by all three organizations.

New and growing enterprises face the challenge of simultaneously executing complex business strategies, building world-class operating teams, creating partnerships, and a wide range of other critical functions with limited resources. The Deerfield External Operations team partners with newly formed, and existing management teams, providing a suite of services designed to enhance company success and growth while reducing timelines to value-creating events and overall costs.  While many companies require significant support early in the life cycle, the External Operations team is structured in a manner that allows Deerfield to be a long-term partner, offering services and assistance to businesses across all stages of maturity, from formation to a successful monetization event.

Services provided by the Deerfield External Operations team, include:

• Human Resources and Talent Acquisition
• Accounting and Financial Management
• Real Estate Sourcing and Negotiation
• Risk Management
• Information Technology
• Sales, Marketing and Other Commercial Support
• Business Strategy and Development
• Contracting Support
• Marketing/Branding/Public Relations
• Investor Relations

Beginning in 2015, Deerfield started the Deerfield Fellows program, designed to attract students with interest in pursuing healthcare or finance fields from local NYC-area colleges and universities from diverse backgrounds for an immersive summer internship program. Successful summer interns are invited to stay through a yearlong Deerfield Fellowship program, with the most successful of those graduating to become Associates at Deerfield. We are extremely proud of the work our Associates do.

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care. As of December 2024, the firm manages more than $15 billion in assets.

Providing value beyond capital, Deerfield generally maintains a combined portfolio of more than 200 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Having many years of operational expertise, Deerfielders are highly engaged and adept at navigating the complex crosscurrents ever-present in the healthcare and financial industries.

Collaboration, intellectual curiosity and pragmatism drive Deerfield’s approach. With its holistic view, Deerfield tailors flexible financing options designed to meet the needs of entrepreneurs and corporate partners.

Meet our team

Deerfield Investment

Supporting companies across the healthcare ecosystem with flexible funding models and value beyond capital.

Search our portfolio

Deerfield Institute

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Institute services

Deerfield Foundation

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Explore our partners

Value beyond capital

Programs

CURE.

At CURE. — Deerfield’s innovation campus on 345 Park Avenue South — we’re transforming healthcare. Here, innovators from across the industry and around the world work shoulder to shoulder to develop treatments to eliminate deadly diseases and create new healthcare delivery models to lower cost and improve care for those in need.

Discover our mission

Established in 2006, the Deerfield Institute delivers sophisticated and timely market research, which enhances the insights available to the investment team and its partners. The Institute develops and analyzes data to advance understanding of innovations and emerging products, and it also informs on trends within the healthcare market. It has published important scientific findings in peer-reviewed journals to extend learnings to the scientific community and benefit public health at large—and  ultimately patients in need. The Institute is guided by Deerfield’s core values: integrity, the pursuit of objective and unbiased research, commitment to excellence, precision and accuracy.

Deerfield Institute Capabilities: 

• Epidemiology
• Scientific Evaluation
• Biostatistics
• Clinical Trial Design, Analysis
• Intellectual Property Evaluation
• Commercial Market Assessment
• Market Access (Pricing, Reimbursement, Access)
• Territory Mapping
• Physician Targeting Plans
• Brand Positioning and Strategic Planning
• Forecasting

PUBLICATIONS

We publish research data to help advance healthcare and to enable researchers to have access to recent, relevant information.

View latest publications

Confidentiality

An affiliate of Deerfield Management, the Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to strive to improve health, accelerate innovation and promote human equity. Since its inception in 2007, the Foundation has formed numerous partnerships and invested in the advancement of children’s health, from clinics in the South Bronx to Nepal. Funds are provided through employee contributions and directly from Deerfield’s profits.

2023 Deerfield Foundation Program Committee

Mark Veich, Executive Director

Kerri Seacord, Treasurer

Julianna Santamaria, Executive Assistant

Abdul Khan, Program Committee Member

Adam Grossman, Program Committee Member

Ankita Shah, Program Committee Member

Bhumika Patel, Program Committee Member

Cecilia Perez, Program Committee Member

Chris Freeland, Program Committee Member

Danielle Rosato, Program Committee Member

David Griffith, Program Committee Member

Elise Wang, Program Committee Member

Emma Giegerich, Program Committee Member

Gabby Briganti, Program Committee Member

George Lytle, Program Committee Member

Giselle Pineda, Program Committee Member

H.C. Huang, Program Committee Member

Huijun Wang, Program Committee Member

Ivo Lorenz, Program Committee Member

John Limanto, Program Committee Member

Kate Lazar, Program Committee Member

Lisa Nordfors, Program Committee Member

Lizzy Baer, Program Committee Member

Luci Albertson, Program Committee Member

Mark Shtilerman, Program Committee Member

Mike Hurley, Program Committee Member

Moses Adubi, Program Committee Member

Nehan Chatoor, Program Committee Member

Nelson Barriocanal, Program Committee Member

Nicole Delgado, Program Committee Member

Rachel Chapin, Program Committee Member

Saiyara Fahmi, Program Committee Member

Sam Becker, Program Committee Member

Terence Fox-Karnal, Program Committee Member

Tori Fleek, Program Committee Member

Deerfield Management recognizes that investigators at research institutions provide much of the novel insights that advance our understanding of disease. However, at any research institution, the most commercially promising innovations eventually outgrow the lab, requiring greater resources and more focused development expertise than a research setting can typically provide.

To bridge that gap, Deerfield partners with leading research centers from across the country, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Together with its research partners, Deerfield has created 20 spin-off companies to date that are supporting key avenues from concept to spin-out of novel therapeutic discoveries, as well as an incubator focused on innovative cardiovascular devices.

Baylor College of Medicine

Blue Square Discoveries

Beth Israel Deaconess Medical Center

Brookline Avenue Innovations

Boston Children’s Hospital

Blackfan Circle Innovations

Broad Institute

Broad Institute

Cold Spring Harbor Laboratory

Harbor Discoveries

Columbia University

Hudson Heights Innovations

Dana-Farber Cancer Institute

Riverway Discoveries

Dana-Farber Cancer Institute

The Center for Protein Degradation

Duke University

Four Points Innovation

Empire Discovery Institute

Empire Deerfield Discovery and Development

Harvard University

Lab1636

MD Anderson Cancer Center

Vescor Therapeutics

Memorial Sloan Kettering Cancer Center, Rockefeller University, Weill Cornell Medicine

Bridge Medicines

Moffitt Cancer Center

Bayfield Therapeutics

Northwestern University

Lakeside Discovery

NYU Langone Health

Amethyst Innovations 

Stanford University

Porter Alliance for Innovative Medicines

The Johns Hopkins University

Bluefield Innovations

The University of Chicago

University of California San Diego

Poseidon Innovation

University of Illinois at Chicago

West Loop Innovations

University of Michigan

Great Lakes Discovery

University of North Carolina at Chapel Hill

Pinnacle Hill

Vanderbilt University

Ancora Innovation

Washington University in St. Louis

Yeda | Weizmann Institute of Science

Orchard Innovations

Far beyond its financial resources—with its long vision, operational expertise, and command in the life science and healthcare space for more than two decades, Deerfield is uniquely positioned to support all stages of development from early-stage to market—advancing science and enabling the translation of ideas into medicines.

Researchers at academic institutions discover many of the novel insights that advance our understanding of disease. Commercially promising innovations eventually outgrow the lab, requiring greater resources and more focused development expertise than an academic setting can typically provide. To address this need, Deerfield has pioneered a model of partnership through research collaborations, which creates the potential for rapid funding and advancement of promising therapies.

Deerfield Discovery and Development (3DC) plays a critical role in progressing early-stage therapeutics from scientific discovery through preclinical proof of concept and into the clinic, via design and execution of relevant experiments. 3DC partners closely with principal investigators in Deerfield’s academic collaboration network, corporate partners and entrepreneurs to provide deep functional expertise and experience across key disciplines. These include:

• Genetic Assessment and Insights
• Chemistry
• In Vitro Pharmacology
• Translational Biology
• Drug Metabolism and Pharmacokinetics
• Safety Assessment
• Chemistry, Manufacturing, and Controls (CMC)
• Clinical & Regulatory
• Project Management